GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » FCF Yield %

Baudax Bio (Baudax Bio) FCF Yield % : -3,281.19 (As of Apr. 30, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Baudax Bio's Trailing 12-Month Free Cash Flow is $-14.31 Mil, and Market Cap is $0.44 Mil. Therefore, Baudax Bio's FCF Yield % for today is -3,281.19%.

The historical rank and industry rank for Baudax Bio's FCF Yield % or its related term are showing as below:

BXRXQ' s FCF Yield % Range Over the Past 10 Years
Min: -17374.68   Med: -503.71   Max: -38.84
Current: -3281.19


During the past 6 years, the highest FCF Yield % of Baudax Bio was -38.84%. The lowest was -17374.68%. And the median was -503.71%.

BXRXQ's FCF Yield % is ranked worse than
98.97% of 1551 companies
in the Biotechnology industry
Industry Median: -15.06 vs BXRXQ: -3281.19

Baudax Bio's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.


Baudax Bio FCF Yield % Historical Data

The historical data trend for Baudax Bio's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio FCF Yield % Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Yield %
Get a 7-Day Free Trial - -79.62 -90.89 -229.71 -538.59

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -316.17 -293.03 -424.42 -169.22 -214.38

Competitive Comparison of Baudax Bio's FCF Yield %

For the Biotechnology subindustry, Baudax Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baudax Bio's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Baudax Bio's FCF Yield % falls into.



Baudax Bio FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Baudax Bio's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-27.813 / 5.1640338
=-538.59%

Baudax Bio's annualized FCF Yield % for the quarter that ended in Sep. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-2.413 * 4 / 4.50219248
=-214.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baudax Bio FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Baudax Bio FCF Yield % Related Terms

Thank you for viewing the detailed overview of Baudax Bio's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341

Baudax Bio (Baudax Bio) Headlines

From GuruFocus

Q2 2020 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Baudax Bio Announces Date of Reconvened Annual Meeting

By sperokesalga sperokesalga 06-06-2023

Baudax Bio Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024

Baudax Bio Announces Pricing of $4 Million Public Offering

By sperokesalga sperokesalga 04-27-2023

Q1 2022 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Baudax Bio Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024